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Total Prostatectomy as a Treatment for Prostatic Carcinoma in 25 Dogs 1 
 2 
ABSTRACT 3 
Objective: To describe the complications and outcome following total prostatectomy in 4 
dogs with histologically-confirmed prostatic carcinoma. 5 
Study Design: Multi-institutional retrospective case series 6 
Animals: Twenty-five client-owned dogs 7 
Methods: Medical rec rds of dogs undergoing total prostatectomy were reviewed from 8 
20014-2016. Data retrieved included signalment, presenting signs, preoperative clinical 9 
findings, including laboratory data, diagnostic imaging, surgical technique, histologic 10 
diagnosis, postoperative complications, occurrence of postoperative metastasis, and 11 
survival.  12 
Results: Twenty-five dogs underwent total prostatectomy for prostatic carcinoma. 13 
Urinary anastomotic techniques included urethrourethral anastomosis in 14 dogs, 14 
cystourethral anastomosis in 9 dogs, ureterocolonic anastomosis in 1 dog, and 15 
anastomosis between the bladder neck and penile urethra in 1 dog. All dogs survived to 16 
discharge. Fifteen dogs were diagnosed with transitional cell carcinoma, 8 dogs with 17 
prostatic adenocarcinoma, 1 dog with prostatic cystadenocarcinoma, and 1 dog with an 18 
undifferentiated carcinoma. Permanent postoperative urinary incontinence was present in 19 
8 dogs. The median survival time was significantly shorter in dogs with extracapsular 20 
tumor extension compared to those with intracapsular tumors. The overall median 21 
survival time was 231 days (range, 24-1255 days) and the 1- and 2-year survival rates 22 
were 32% and 12%, respectively.  23 
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Conclusions: Based on information from this study, the median survival time for dogs 24 
with prostatic carcinoma undergoing total prostatectomy is longer and complication rates 25 
lower than previously reported.  26 
 27 
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INTRODUCTION 47 
Prostatic neoplasia is relatively rare in dogs
1 
making evaluation of various therapeutic 48 
interventions difficult. Despite the uncommon occurrence in dogs, they are one of the few 49 
domestic species known to develop spontaneous prostatic neoplasia,
 
with carcinomas 50 
being the most common histologic diagnosis.
2, 3
 Prostatic carcinomas include transitional 51 
cell carcinoma, adenocarcinoma, and squamous cell carcinoma
4
. Attempts have been 52 
made to develop more objective methods than traditional light microscopy for 53 
differentiating prostatic adenocarcinoma and transitional cell carcinoma
4
. To the authors’ 54 
knowledge there is not yet a well accepted objective method of differentiation and the 55 
distinction between adenocarcinoma and transitional cell carcinoma of the prostate 56 
remains controversial. 57 
Prostatic neoplasia carries a poor prognosis in dogs because of aggressive local invasion 58 
and a high rate of regional and distant metastasis.
5
 Hematuria, stranguria and tenesmus 59 
are common clinical signs in dogs with prostatic disease,
1,6
 but a diagnosis of prostatic 60 
neoplasia is often delayed because these clinical signs are not pathognomonic for 61 
prostatic tumors. A diagnosis of prostatic neoplasia is mad  based on physical 62 
examination findings, diagnostic imaging, cytology, and histology. Metastatic disease is 63 
often present at the time of initial diagnosis.
1,6
  64 
Various treatments have been described for prostatic neoplasia including non-steroidal 65 
anti-inflammatory drugs (NSAIDs), chemotherapy, radiation therapy, photodynamic 66 
therapy, and surgery. Surgical options include curative-intent total prostatectomy and 67 
palliative-intent procedures such as partial prostatectomy, transurethral resection, 68 
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radiation therapy, photodynamic therapy, urethral stenting, and urinary diversion 69 
procedures.
 7-16
 70 
Improved survival in dogs with urogenital carcinoma has been shown with the use of 71 
non-steroidal anti-inflammatory drugs (NSAIDs) alone and in combination with 72 
chemotherapeutic agents such as mitoxantrone and carboplatin.
17-20 
Reported survival 73 
times in dogs with prostatic malignancies vary widely, depending on the stage at 74 
diagnosis and treatment pursued.
6,7,9-11,13,14, 20-22 
Furthermore current therapeutic strategies 75 
have been associated with poor response and high complication rates.  76 
Total prostatectomy involves removal of the entire prostate gland and prostatic urethra 77 
with subsequent reconstruction of the lower urinary tract. Criteria for appropriate case 78 
selection for total prostatectomy in dogs have been previously suggested to include small, 79 
intracapsular primary lesions, without evidence of metastatic disease.
23
 There have been 80 
few reports evaluating total prostatectomy with most concluding that complication rates 81 
are too high and survival times are too short to routinely recommend this technique for 82 
treatment of dogs with prostatic neoplasia.
21,22,24-26 
The most common complication 83 
reported following total prostatectomy is urinary incontinence, which has been reported 84 
in 33-100% of cases.
24,27
  85 
The purpose of this retrospective multi-institutional study was to report the signalment, 86 
presenting signs, intraoperative and postoperative complications, histologic diagnosis, 87 
and outcome in dogs treated with total prostatectomy for prostatic neoplasia. We 88 
hypothesized total prostatectomy would be associated with a complication rate and 89 
survival time similar to other currently available therapeutic interventions. 90 
 91 
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MATERIALS AND METHODS 92 
This investigation was a multi-institutional retrospective case series approved by the 93 
Veterinary Society of Surgical Oncology Research Committee. The study period ranged 94 
from October 2004 to August 2016. Medical records from contributing institutions were 95 
searched to identify dogs which had undergone total prostatectomy for prostatic 96 
neoplasia. Dogs were included if they had undergone total prostatectomy for confirmed 97 
prostatic carcinoma. Dogs were excluded where the diagnosis was not confirmed to be 98 
carcinoma. Data retrieved included neuter status, breed, age, body weight, presenting 99 
clinical signs, dates of presentation and surgery, results of preoperative staging and 100 
diagnostic testing, surgical technique, use and duration of postoperative indwelling 101 
urethral catheterization, histologic criteria (histologic diagnosis, surgical margin 102 
evaluation, and presence of lymphatic and/or vascular invasion), postoperative 103 
complications (incidence and severity), use of adjunctive therapy, date and method of 104 
detection of recurrent disease, and date and cause of death. Postoperative complications 105 
were classified as minor or major. Minor complications were defined as self-limiting or 106 
those managed with medical intervention. Major complications were defined as any 107 
complication that was expected to cause death without rapid intervention or those 108 
requiring a second surgical procedure. Postoperative urinary incontinence was graded 109 
from 0-4 using a scheme modified from that reported by Byron et al. (Table 1)
28 
with 110 
information recorded from veterinarian assessment and owner reporting in the medical 111 
history. 112 
Disease-free interval (DFI) was defined as the time between total prostatectomy and 113 
detection of confirmed or suspected metastasis or local recurrence of neoplasia. 114 
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Metastasis was suspected if there were consistent imaging or clinical examination 115 
findings  and was confirmed with cytology or histology. Tumor recurrence was suspected 116 
if there was a recurrence of clinical signs or if imaging findings were consistent with a 117 
recurrent mass in the region of the previous surgical site; and tumor recurrence was 118 
confirmed with cytologic or histologic evidence of neoplasia.  119 
Survival time was defined as the time between total prostatectomy and death. Cause of 120 
death was classified as either tumor-related or unrelated. Dogs for which the cause of 121 
death was unknown were presumed to have died or been euthanized as a result of tumor-122 
related causes. Dogs that died from unrelated causes or were still alive at the time of 123 
writing were censored from the survival analysis.   124 
 125 
Statistical Analysis 126 
Descriptive statistics for signalment, historical, preoperative, and postoperative data were 127 
generated and reported as the arithmetic mean and range. Disease-free intervals and 128 
survival times were reported as medians with 95% confidence intervals. Median survival 129 
times (MST) were estimated from Kaplan-Meier survival analysis. A log-rank test was 130 
used to compare survival curves of dogs with transitional cell carcinoma and prostatic 131 
adenocarcinoma. P ≤ 0.05 was considered significant. Statistical software (Medcalc 132 
version 16.8.4 for Windows, Medcalc Software, Ostend, Belgium, www.medcalc.org) 133 
was used for descriptive statistical modelling and Kaplan-Meier survival analysis.  134 
 135 
 136 
 137 
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RESULTS  138 
Signalment  139 
Twenty-five dogs met the inclusion criteria. The median age was 9.3 years (range 4.9-140 
13.0 years). The median weight was 25.0 kg (range 6.1-47.4 kg). All dogs were neutered 141 
males. Breeds were Labrador retriever (n=5), mixed breed (5), German shepherd (2), and 142 
1 each of West Highland White Terrier, Lhasa Apso, Boxer, Dachshund, Jack Russell 143 
Terrier, Australian Cattle Dog, Siberian Husky, American Staffordshire Bull Terrier, 144 
Wheaten Terrier, Rhodesian Ridgeback, Shetland Sheepdog, Boston Terrier, and Golden 145 
Retriever (Table 2). 146 
 147 
Clinical Findings 148 
The most common clinical signs on presentation were dysuria (n=12), dyschezia (6), 149 
gross hematuria (6), pollakiuria (6), hyporexia (4), and lethargy (4). Prostatic 150 
enlargement was detected incidentally on routine digital rectal examination in 4 dogs. 151 
Two dogs presented with pre-existing urinary incontinence (grade 2, n=1; grade 4, 1).  152 
An enlarged prostate palpated on rectal examination was the most common physical 153 
examination finding (n=16). A caudal abdominal mass was detected on abdominal 154 
palpation in 2 dogs.  155 
 156 
Preoperative Diagnostic Tests 157 
Preoperative serum biochemistry, hematology and urinalysis results were available for 158 
24, 23, and 24 dogs, respectively. Serum biochemistry abnormalities included increased 159 
alkaline phosphatase (n=4; 227-634 U/L [reference range, 23-212 U/L]), increased 160 
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alanine transferase (2; 189-657 U/L [reference range, 10-125 U/L]), and 161 
hypertriglyceridemia (1; 539 mg/dL [reference range, 20-112 mg/dL]). Hematologic 162 
abnormalities included anemia (1; 4.88 x10
12
 cells/L [reference range, 5.65-8.87 163 
x10
12
/L]), neutrophilia (4; 12.5-24.6 x 10
9
/L [reference range,  2.95-11.64 x10
9
/L]) and 164 
monocytosis (1; 3.01x10
9
/L [reference range, 0.16-1.12 x10
9
/L]). Urinalysis 165 
abnormalities included hematuria (13) and neoplastic epithelial cells on sediment 166 
examination (1). Urine was cultured preoperatively in 6 dogs and 3 of these were 167 
positive, including Streptococcus canis (1), Gram negative rods and Gram positive rods 168 
and cocci (1), and a positive culture without further information available (1).  169 
Preoperative imaging for clinical staging included three-projection thoracic radiographs 170 
(n=20), orthogonal abdominal radiography (3), abdominal ultrasonography (19), thoracic 171 
and abdominal computed tomography (CT) (8), and abdominal magnetic resonance 172 
imaging (MRI) (1). No dog had evidence of pulmonary metastatic disease. 173 
Prostatomegaly was detected in all but one dog. The prostate was intrapelvic and not 174 
detected on abdominal ultrasonography in this dog. Additional imaging findings included 175 
mild internal iliac lymphadenomegaly (3), pyelectasia (1), and ureteral dilation (1).  176 
Preoperative cytology (20) and histopathology (3), reports were available for 23 dogs. 177 
Cytology results included carcinoma, not further classified in (17), epithelial dysplasia 178 
(2) and squamous metaplasia (1). Histology results were in agreement with the final post-179 
operative diagnosis in all three cases with transitional cell carcinoma in 2 dogs and 180 
prostatic adenocarcinoma in 1 dog.  181 
 182 
 183 
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Total Prostatectomy 184 
The prostate was approached via a caudal ventral midline celiotomy in all dogs. Pubic 185 
and ischial osteotomies (n=3) or pubic symphysiotomy (2) were required for further 186 
exposure in 5 dogs with an intrapelvic prostate. Enlarged medial iliac lymph nodes were 187 
detected intra-operatively and removed for histologic evaluation in 2 dogs. A retrograde 188 
urinary catheter was placed in all dogs prior to prostatectomy. The deferent ducts were 189 
ligated and transected. The periprostatic fat was dissected from the prostate, with 190 
dissection as close as possible to the prostatic capsule, especially dorsally, to minimize 191 
the risk of iatrogenic damage to the neurovascular supply to the urinary bladder and 192 
urethra. The prostatic vascular supply was ligated or cauterized as close to the prostate as 193 
possible. The urinary catheter was then partially withdrawn to allow for pre- and post-194 
prostatic urethral transection before advancing the catheter back into the bladder 195 
following completion of the total prostatectomy. Urethrourethral anastomosis was 196 
performed in 14 dogs and cystourethral anastomosis in 9 dogs. One dog had gross disease 197 
extending into the bladder and post-prostatic urethra. A total cystoprostectomy was 198 
performed with bilateral ureterocolonic anastomosis in this dog. Another dog had gross 199 
disease involving a large section of the post-prostatic urethra and an anastomosis between 200 
the bladder neck and penile urethra was performed. The suture materials and patterns 201 
used for anastomosis were recorded for 19 dogs. Anastomosis was performed with a 202 
monofilament absorbable suture in all dogs using either a simple interrupted (11) or a 203 
simple interrupted and simple continuous pattern (8). Closure of the celiotomy incision 204 
was routine.  205 
 206 
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Postoperative Management 207 
A urinary catheter was maintained postoperatively in 20 dogs for a median of 4 days 208 
(range, 1-7).  209 
All dogs were treated with postoperative analgesia and protocols were variable including 210 
NSAIDs (n=22), opioids (20), tramadol (9), ketamine (1), and acetaminophen (1).  211 
 212 
Surgical Complications and Outcome 213 
All dogs survived to discharge and no intraoperative or perioperative deaths were 214 
recorded. There were 4 major complications in 4 dogs and 16 minor complications in 15 215 
dogs. 216 
Major complications included minor incisional dehiscence (n=2), uroabdomen (1), and 217 
prepubic herniation (1). Revision surgery was performed in all dogs with major 218 
complications. Uroabdomen was detected 1 day post-operatively in 1 dog and a 15 mm 219 
laceration was found at the bladder neck. This was presumed to be iatrogenic. Prepubic 220 
herniation occurred 20 days post-operatively in another dog and was repaired with 221 
polypropylene mesh. 222 
Minor complications included permanent urinary incontinence (n=8), urinary tract 223 
infection (6), and superficial surgical site infection (2).  224 
Postoperative urinary incontinence was recorded in 23 dogs overall. Eleven dogs had 225 
grade 0 urinary incontinence. Urinary incontinence resolved completely in 3 additional 226 
dogs within 1-4 weeks postoperatively. In 1 dog, continence was maintained when treated 227 
with phenylpropanolamine. Eight dogs exhibited some degree of permanent urinary 228 
incontinence: grade 1 (n=2), grade 2 (3), grade 3 (1) and grade 4 (2). One of the dogs 229 
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with grade 4 urinary incontinence had pre-existing grade 4 urinary incontinence. Fifteen 230 
dogs returned to complete urinary continence within 4 weeks; although recurrent urinary 231 
incontinence, secondary to suspected local tumor recurrence, was recorded in 1 dog 148 232 
days after surgery (Table 2). Some degree of post-operative urinary incontinence was 233 
seen in 4 of 9 dogs with cystourethral anastomosis (one of which was pre-exisiting) and 4 234 
of 11 dogs with urethrourethral anastomosis.  235 
 236 
Histologic Diagnosis 237 
Histologic examination of the excised prostate was performed in all dogs, with a report 238 
available in 20 dogs. Diagnoses included transitional cell carcinoma (n=15), 239 
adenocarcinoma (8), undifferentiated carcinoma (1), and papillary cystadenocarcinoma 240 
(1).  For the two dogs with sublumbar lymph node excision, one dog had evidence of 241 
nodal metastasis and the other dog had a reactive lymph node.  242 
Of the 20 dogs with histologic margin evaluation, 8 dogs had complete excision and 12 243 
dogs had incomplete excision. Local recurrence was either suspected or confirmed in 3 244 
dogs with complete histologic margins and in 4 dogs with incomplete margins. There was 245 
no significant difference in the rate of local recurrence between dogs with complete 246 
histologic margins compared to those with incomplete margins (P = 0.84). There was 247 
histologically diagnosed extracapsular extension in 11 dogs and no evidence of 248 
extracapsular extension in 9 dogs. There was no significant difference in the rate of local 249 
recurrence between dogs with extracapsular extension and those without extracapsular 250 
extension (P = 0.44). There was histologic evidence of lymphatic and/or vascular 251 
invasion in 13 dogs and no evidence of lymphatic and/or vascular invasion in 7 dogs. 252 
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Metastatic disease was either confirmed or suspected in 7 dogs with lymphatic and/or 253 
vascular invasion and in 2 dogs without lymphatic and/or vascular invasion. There was 254 
no significant difference in the rate of metastasis between dogs with lymphatic and/or 255 
vascular invasion compared to those without lymphatic and/or vascular invasion (P = 256 
0.29).  257 
There was no significant difference in MSTs between dogs with and without complete 258 
histologic margins or dogs with and without lymphatic and/or vascular invasion (P = 0.23 259 
and 0.11, respectively). The MST was significantly shorter in dogs with extracapsular 260 
extension compared to those with intracapsular tumors (P = 0.02) (Table 3).  261 
 262 
Adjuvant Therapy 263 
Twenty-one dogs received adjunctive therapy, including mitoxantrone and NSAIDs 264 
(n=14); NSAIDs alone (3); metronomic thalidomide, cyclophosphamide, and piroxicam 265 
(3); and carboplatin and deracoxib (1). Dosing and protocols were variable, but of the 15 266 
dogs treated with curative-intent chemotherapy protocols, 10 dogs completed their 267 
targeted chemotherapy protocols. Of the five dogs that did not complete their protocols 268 
reasons for termination of the protocol were available for 3 dogs and were all due to the 269 
development of metastatic disease. Adverse effects were recorded for 2 dogs both of 270 
which were episodes of neutropenia during treatment with mitoxantrone and piroxicam 271 
which resolved with dose reduction of mitoxantrone. 272 
One dog was treated with adjunctive radiation therapy to the local surgical site (27 Gy 273 
divided into 10 fractions of 2.7 Gy daily, Monday through Friday), starting 20 days 274 
following total prostatectomy and bilateral medial iliac lymphadenectomy. 275 
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Clinical Outcome 276 
Local tumor recurrence was confirmed in 3 dogs and suspected in 5 dogs. Metastatic 277 
disease was confirmed in 4 dogs and suspected in 9 dogs. Confirmed metastatic sites 278 
included lungs (n=1), sublumbar lymph nodes (1), sublumbar lymph nodes and pelvis (1), 279 
and lungs, pelvis, vertebrae, adrenal glands and sublumbar lymph nodes (1). Sites of 280 
suspected metastasis included lungs (6), skin (1), bone (1) and sublumbar lymph nodes 281 
(1). 282 
Data to calculate the DFI was available for 14 dogs. The median DFI was 81.5 days (95% 283 
confidence interval (CI) 48.4-263, range 11.0-630 days). Data to calculate the median 284 
DFI was available for 5 dogs with suspected or confirmed local recurrence (median DFI 285 
85.0 days, 95% CI 27.7-208.7, range 76-247) and 9 dogs with suspected or confirmed 286 
metastatic disease (median DFI 76.0 days, 95% CI 31.4-305, range 24.0-630). Two dogs 287 
with recurrent disease were still alive at the time of writing 65 and 190 days post-288 
operatively.  289 
 290 
Death was attributed to tumor-related causes in 19 dogs: local recurrence in 7 dogs 291 
(confirmed in 2 dogs and suspected in 5 dogs) and metastasis in 12 dogs (confirmed in 3 292 
dogs and suspected in 9 dogs). Three dogs were euthanized for reasons unrelated to 293 
prostatic neoplasia. Two dogs were euthanized for clinical progression of chronic kidney 294 
disease; and 1 dog was euthanized for suspected degenerative myelopathy. Three dogs 295 
were still alive at the time of writing, ranging from 65-1255 days post-operatively. 296 
The MST for all dogs was 231 days (95% CI 138-628, range 24-1255 days). The MST 297 
for dogs with prostatic transitional cell carcinoma was 189 days (95% CI 135-628, range 298 
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34.0-664) and the MST for dogs with prostatic adenocarcinoma was 248 days (95% CI 299 
169-789 days, range 24-1255 days). There was no significant difference in MSTs 300 
between dogs with transitional cell carcinoma and adenocarcinoma (P = 0.27). The 1- and 301 
2-year survival rates following total prostatectomy were 32% and 12% of dogs, 302 
respectively. 303 
 304 
 305 
 306 
 307 
 308 
 309 
 310 
 311 
 312 
 313 
 314 
 315 
 316 
 317 
 318 
 319 
 320 
 321 
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DISCUSSION 322 
This report describes the surgical technique and outcome of dogs undergoing total 323 
prostatectomy for the treatment of prostatic carcinoma. The signalment and clinical 324 
presentation of dogs in the present study was similar to previous reports of dogs with 325 
prostatic tumors.
6,29
 326 
Total prostatectomy has been associated with an unacceptably high complication rate in 327 
previous studies in dogs.
21, 23, 24-27 
However, the majority of these studies included total 328 
prostatectomy for treatment of various prostatic diseases and only one specifically 329 
investigated total prostatectomy for treatment of prostatic neoplasia.
21
 In this study, 330 
survival times were short (range, 5-45 days) and the incidence of urinary incontinence 331 
was not described.
21
 However, urinary incontinence was the most common postoperative 332 
complication in other studies of total prostatectomy for dogs with prostatic diseases, with 333 
an incidence ranging from 33%-100%.
24,26, 27 
Permanent postoperative urinary 334 
incontinence was recorded in 34.8% of dogs in the present study. The severity of urinary 335 
incontinence was subjectively graded based on owner and veterinary assessment. Of the 8 336 
dogs with permanent urinary incontinence, 5 dogs had grade 1 or 2 urinary incontinence. 337 
A previous study classified the severity of urinary incontinence following total 338 
prostatectomy as minor if it only occurred with excitement or activity, and major if it was 339 
permanent.
27
 If this classification were used in the present study then only 17.4% of dogs 340 
(4/23) would have been assessed to have major urinary incontinence. A grading system to 341 
describe the severity of urinary incontinence may assist owners in determining whether 342 
the postoperative outcome will be compatible with their expectations. Permanent urinary 343 
incontinence may lead to secondary complications such as recurrent urinary tract 344 
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infection, pyelonephritis, and urine scalding; and owners should be aware of these 345 
possible sequalae.  346 
Urinary incontinence has been assessed in both normal dogs and dogs with prostatic 347 
disease undergoing total prostatectomy.
24,31
 For dogs without prostatic disease, total 348 
prostatectomy does not result in urinary incontinence.
31
 However, in another study by the 349 
same authors, 93% of dogs with prostatic disease had urinary incontinence following 350 
total prostatectomy with 54% of these dogs having permanent incontinence.
24
 This 351 
suggests that the disease process itself may play a role in the development of urinary 352 
incontinence, and urinary incontinence may not solely be a consequence of the surgical 353 
technique. This is further supported by a study in which the surviving 3 dogs that 354 
underwent inadvertent prostatectomy during cryptorchidectomy did not have urinary 355 
incontinence following surgical correction.
32
 In normal dogs treated with total 356 
prostatectomy, there were minimal functional changes to the urinary tract, but there was a 357 
decrease in the maximal urethral closing pressure in these dogs.
31
 However, this decrease 358 
in maximal urethral closing pressure was not sufficient for urethral sphincter pressure to 359 
be overcome by intravesicular pressure.
31 
Dogs with prostatic disease have abnormally 360 
low external urethral sphincter pressures.
24
 This reduced external urethral sphincter 361 
pressure, in combination with a decrease in maximal urethral closing pressure following 362 
total prostatectomy, likely predisposes to urinary incontinence in dogs with prostatic 363 
disease.  364 
Surgical technique may also influence the development of urinary incontinence post-total 365 
prostatectomy. The neurovascular supply to the bladder neck and prostatic urethra 366 
courses along the dorsal aspect of the prostate and disruption of this neurovascular supply 367 
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during total prostatectomy may result in urinary incontinence postoperatively.
27
 Total 368 
prostatectomy was performed in all dogs in the present study with close attention to the 369 
dorsal dissection technique to minimize the risk of disrupting the innervation to the 370 
bladder neck and proximal urethra.  371 
It is possible that the comparatively low rate of urinary incontinence in the present study 372 
is related to the primary pathology. However, it has been suggested that total 373 
prostatectomy in dogs with prostatic neoplasia may be associated with a higher incidence 374 
postoperative incontinence compared to other causes of prostatic pathology.
27
  The 375 
numbers in that study were small with only 3 of 9 dogs being diagnosed with prostatic 376 
neoplasia, two of which were carcinomas. Case selection may also have played in role in 377 
the lower rate of urinary incontinence in the present study as dogs may not have been 378 
deemed appropriate surgical candidates if there was gross disease extending beyond the 379 
prostatic capsule. This may have contributed to less aggressive dissection being required 380 
to excise the prostate thus limiting collateral damage to the surrounding neurovascular 381 
structures. 382 
Adjunctive treatment was used in the majority of the dogs in this study, with 21 dogs 383 
receiving some form of adjunctive therapy following total prostatectomy. While no 384 
comment can be made on the adjunctive treatment protocol of choice, adjunctive 385 
treatment is still recommended for dogs with prostatic carcinoma because of the high risk 386 
of metastatic disease. Additionally, because very few dogs in this study were treated with 387 
total prostatectomy alone, no comparison of outcome for surgical intervention with and 388 
without adjunctive therapy can be made from this population.  389 
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There was no significant difference found between completeness of histologic margins or 390 
the presence extracapsular extension and local recurrence of prostatic carcinoma. There 391 
was no significant difference in MST between dogs with local recurrence of prostatic 392 
carcinoma compared to those without local recurrence; however the MST was 393 
significantly shorter for dogs with extracapsular extension compared to those with 394 
intracapsular tumors. The reason for this difference is unclear. Since there was no 395 
association found between extracapsular extension and local recurrence; or local 396 
recurrence and MST, it is unlikely that extracapsular extension contributed to the 397 
significant difference in MST as a consequence of an increased rate of local recurrence. 398 
Nonetheless the significantly shorter survival time of dogs with extracapsular extension 399 
indicates that this information may be of prognostic value.  400 
There was no association found between the presence of lymphatic and/or vascular 401 
invasion at the time of surgery and the occurrence of metastatic disease. Likewise there 402 
was no association found between the presence of lymphatic and/or vascular invasion and 403 
MST. Overall metastatic disease was either suspected or confirmed in 13 of 25 dogs 404 
(52.0%). This is comparable to previous reports where metastasis to sublumbar 405 
lymph nodes, bone, and lungs was reported in 63–89% of dogs at the time of diagnosis.
8
 406 
There was no significant difference in survival time between dogs with transitional cell 407 
carcinoma or adenocarcinoma. Some authors have referred to prostatic neoplasia with 408 
various morphologic features, such as glandular and urothelial differentiation, 409 
collectively as prostatic carcinoma
6
 as we have done in the present study.
 
This may be 410 
reasonable given the lack of a proven objective means of differentiation. Given the 411 
similar morphologic features of prostatic adenocarcinoma and transitional cell carcinoma 412 
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when assessed using light microscopy it may be difficult to distinguish the precise cell 413 
origin.
4
 Immunohistochemical methods have been investigated for the purpose of 414 
differentiating prostatic adenocarcinoma from transitional cell carcinoma but as yet a 415 
valid method has not been found.
4 
Accurate classification of prostatic epithelial neoplasia 416 
may be significant from a prognostic perspective though currently this remains 417 
controversial. 418 
The MST time for dogs undergoing total prostatectomy for prostatic carcinoma in this 419 
study was 231 days (Figure 1). All dogs survived to discharge and almost one-third of 420 
dogs survived longer than one year following total prostatectomy. A MST of 17 days was 421 
reported in the only other study to report a MST following total prostatectomy in dogs 422 
with prostatic neoplasia
21
  Published survival times for prostatic carcinoma including 423 
various other treatments range from 17 to 654 days (Table 4).
7-9,11,14,21,22,30, 33
 However a 424 
number of these studies included cases with urogenitial carcinomas arising from locations 425 
other than the prostate and did not provide separate analysis of survival for patients with 426 
prostatic carcinoma alone.
11, 18, 33
 427 
The MST in this study population is markedly longer than that previously published for 428 
dogs with prostatic carcinoma following total prostatectomy. The study by Vlasin, et al.
21
 429 
reporting a MST of 17 days in dogs was prospective and randomised. This study design 430 
may have contributed, in part, to the poor overall survival of those dogs as randomization 431 
may have prevented selection of cases most appropriate for total prostatectomy. In 432 
contrast the retrospective nature of our report may have resulted in reporting of cases 433 
deemed more suitable for total prostatectomy by the surgeon. While no reported effort 434 
was made to select cases with primary lesions under a certain size and without 435 
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extracapular extension or pre-existing metastatic disease, it is reasonable to assume that 436 
these factors played a role in case selection. Only one case in this study had documented 437 
metastatic disease prior to total prostatectomy. 438 
The limitations of this study are shared with other multi-institutional retrospective 439 
studies. Medical records can be inaccurate or incomplete. There was no standardization 440 
of perioperative or adjunctive treatments, and the surgeons performing the procedure 441 
differed. The cause of death was only confirmed by post-mortem evaluation in 4 dogs. 442 
Retrospective inference of the degree of post-operative urinary incontinence from owner 443 
and veterinarian descriptions may be inaccurate. Also, the power of statistical analyses 444 
performed was likely limited by the small sample size.  445 
Based on our findings, total prostatectomy may be considered as a viable treatment 446 
option in dogs with prostatic neoplasia, particularly if presenting with urethral 447 
obstruction. However, we propose that case selection is likely to play an important role in 448 
postoperative complications and survival. Our study suggests that the incidence and 449 
severity of urinary incontinence in dogs with prostatic carcinoma treated with total 450 
prostatectomy may be lower and survival times longer than previously reported. Further 451 
prospective evaluation of risk factors for post-operative complications and outcome 452 
following total prostatectomy in dogs is necessary to determine appropriate case selection 453 
criteria. 454 
 455 
 456 
 457 
 458 
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Table 1 Urinary Incontinence Scoring System* 
 
0 Dog always continent 
1 Dog urine soils where is has been sleeping more than 
50% of the time. Does not dribble urine or have a wet 
prepuce/ventrum when awake. 
2 Dog urine soils where it has been sleeping more than 
50% of the time. Dribbles urine or has a wet prepuce 
when awake up to 25% of the time. 
3 Poorly continent. Dog urine soils where it has been 
sleeping more than 50% of the time and has a wet 
prepuce/ventrum 25-75% of the time. 
4 Dog is never continent. Dribbles urine when awake 
and when sleeping. Constantly has a wet 
prepuce/ventrum and leaves urine when rising from a 
sitting to standing position. 
 
*Modified from Byron, et al.28 
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Figure 1 Kaplan-Meier survival curve for 25 dogs with prostatic carcinoma that underwent total prostatectomy. Dogs were censored from 
analysis if they were still alive at the time of writing or if they had died from causes unrelated to prostatic neoplasia. 
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Table  Signalment, diagnosis, surgery details, incontinence and outcome for dogs undergoing total prostatectomy 
Dog Age (years) Breed Surgical Technique Postoperative 
urinary catheter 
duration (days) 
Diagnosis† Urinary Incontinence 
Score‡ 
Survival Times 
(days) 
Cause of death 
1 10.6 Labrador retriever CU 2 PA 3 789 Euthanasia (renal insufficiency) 
2 11.3 West-Highland terrier CU 2 TCC 0
§
 190 Alive  
3 4.9 Lhasa apsoa UU 1 TCC 0 628 Euthanasia (suspected metastasis) 
4 12.75 mixed breed CU 4 TCC 2 34 Euthanasia (confirmed pulmonary metastasis) 
5 9.3 boxer UU 4 TCC 1 489 Euthanasia (renal insufficiency) 
6 10.58 dachshund UU 1 TCC 0 231 Euthanasia (confirmed local recurrence) 
7 9.25 mixed breed CU 1 TCC 2 135 Euthanasia (suspected local recurrence) 
8 8.5 Jack Russell terrier CU 2 PA 0 172 Euthanasia (suspected local recurrence) 
9 7.9 Australian cattle dog UU 2 TCC 4 134 Euthanasia (suspected local recurrence) 
10 8.25 Siberian husky UU 3 PA 0 65 Alive 
11 11 German shepherd UU 5 PA 0 798 Euthanasia (suspected degenerative myelopathy) 
12 8 mixed breed UU 7 PA 0 1255 Alive 
13 7.66 American Staffordshire bull terrier CU 3 PA  0
§ 
169 Euthanasia (suspected metastasis) 
14 6.5 wheaten terrier UU n/a TCC 2 99 Euthanasia (suspected local recurrence and metastasis) 
15 10 golden retriever UU n/a TCC 0
¶
 189 Unknown 
16 10 Labrador retriever CU n/a TCC 0
§
 396 Euthanasia (suspected metastasis) 
17 10 Labrador retriever CU n/a TCC 4 (pre-existing) 647 Euthanasia (suspected metastasis) 
18 9 Rhodesian ridge back UU 5 TCC 0 664 Euthanasia (confirmed local lymph node metastasis) 
19 10 mixed breed UU 7 PA 0 248 Euthanasia (suspected local recurrence) 
20 9 Shetland sheepdog UU 5 PA 1 31 Euthanasia (confirmed multifocal metastatic disease) 
21 12 Labrador retriever UU 5 TCC 0 88 Euthanasia (suspected metastasis) 
22 9 Boston terrier 
Anastomosis between 
bladder neck and 
penile urethra 7 PA Unknown 24 Euthanasia (suspected metastasis) 
23 13 German shepherd 
Ureterocolonic 
anastomosis n/a TCC n/a 138 Euthanasia (melena and lethargy) 
24 9 mixed breed  UU 7 TCC 0 149 Euthanasia (confirmed local recurrence) 
25 9 Labrador retriever CU 5 PCA 0 330 Euthanasia (suspected metastasis) 
 
*Urethrourethral anastomosis (UU), cystourethral anastomosis (CC) 
† 
Prostatic carcinoma (PA), transitional cell carcinoma (TCC), prostatic cystadenocarcinoma (PCA) 
‡
 Modified from Byron et al
28 
§
Had initial post-operative incontinence which resolve 
¶ 
No incontinence when on phenylpropanolamine. Incontinence recurred 148 days post-operatively, suspected secondary to local recurrence 
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Table 3 Comparison of MST with and without lymphatic/vascular invasion, extracapsular extension and complete histologic margins 
MST  With 
Lymphatic/vascular 
Invasion 
Without 
Lymphatic/vascular 
Invasion 
With Extracapsular 
Extension 
Without 
Extracapsular 
Extension 
With Complete 
Histologic Margins 
Without Complete 
Histologic Margins 
MST 149 248 138 248 248. 172 
95% CI 99.0-189 135-664 88.0-169 172-628 99.0-628 134-396 
P value 0.12 
 
0.02 
 
0.23 
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Table 4 Published Survival Times in Dogs with Prostatic Carcinoma 
Reference Treatment MST (range) 
Vlasin et al21 Total prostatectomy 17 days (5-45) 
Vlasin et al21  Subtotal intracapsular prostatectomy 130 days (2-220) 
Liptak et al8 Transurethral resection 32, 74, and 264 days 
L’Epplattenier et al30 Partial prostatectomy with Nd:YAG laser 103 days (5-239)* 
Weisse et al11 Urethral stenting  20 days (6-105) † 
L’Epplattenier et al14 Photodynamic therapy with 5-aminolevulinic acid 41 days (10-68) 
Turrel et al9 Intraoperative radiation therapy 114 days (41-750) 
Nolan et al33 Intensity modulated and image guided radiation therapy 654 days‡ 
Sorenmo et al18 NSAIDS 6.9months  
Sorenmo et al18 Untreated 21 days  
 
*Excluding the three dogs that died within 16 days MST =183 (91-239) 
†Survival time for all 12 dogs in this study (survival for cases with prostatic carcinoma not reported separately). 
‡
 Survival time for all 21 dogs in this study (survival for cases with prostatic carcinoma were not reported separately). 
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